Board Committees in a Five-Seat Biopharma
Board Committees in a Five-Seat Biopharma
The standard model of board committees comes from large-cap public company governance, where boards of ten to fourteen directors distribute their oversight work across an Audit Committee, a Compensation Committee, a Nominating and Governance Committee, and often a Risk Committee, a Science and Technology Committee, and others besides. Each committee has three to five members, no director sits on too many, and the work is genuinely parallelized. This architecture is what governance manuals describe, what listing standards assume, and what most director education programs teach.
It is also what a clinical-stage biopharma board with five seats cannot use.
The committee question in a small biopharma is structurally different. The same three independent directors who are doing the work of an audit committee are also doing the work of a compensation committee, a nominating committee, and whatever else the company needs. The choice is not which committees to constitute. The choice is how to allocate scarce oversight capacity across the work that committees are nominally supposed to do, what genuinely requires committee infrastructure, and what is better handled by the full board acting as a committee of the whole.
This article works through that allocation question — the committees that genuinely need to exist in a clinical-stage company, the committees that should not, the special case of a Science and Research Committee, and the design choices that become consequential as the company approaches a public listing or a transaction.
What Committees Are For
Before working through which committees a small biopharma should constitute, it is worth being clear about what committees actually do, because the answer changes the analysis.
A committee performs three functions that the full board cannot perform as efficiently. The first is depth of engagement: a three-person committee can spend the time needed to develop a real understanding of a complex area — auditor performance, executive compensation philosophy, director recruitment — without consuming the bandwidth of the full board. The second is independence from management: a properly constituted committee, meeting in executive session, can engage with sensitive matters that would be filtered or compromised if discussed only in the presence of the CEO. The third is structural authority: certain committees have decision rights conferred by listing standards, by the company's bylaws, or by regulatory requirements that the full board cannot override.
The first two functions matter most in private clinical-stage companies. The third matters most as the company approaches a public listing. Both points should shape how a small biopharma board thinks about its committee structure — what it actually needs now, and what it will need to be ready to constitute later.
The Audit Committee
The Audit Committee is the one committee that every biopharma board needs from very early in the company's life, and it is the one committee whose design choices have the most consequential downstream implications.
In a pre-IPO private company, there is no listing-standard requirement to have an audit committee at all. Many small biopharma companies operate for years without one, with the CEO and CFO presenting financial information directly to the full board. This is workable, but it is workable in the way that operating without a fire alarm is workable. The audit committee exists to do the work that no one else in the company has the right combination of independence, expertise, and authority to do: to engage directly with the external auditor without management present, to assess the quality of internal controls, and to receive whistleblower communications through a channel that does not flow through management.
The composition question is where the constraint of the five-seat board becomes acute. Once the company is public, US listing standards require an audit committee composed entirely of independent directors, and the SEC requires the company to disclose whether at least one of those directors qualifies as a financial expert. In a board with three independent directors, this means the audit committee is effectively the three of them, and at least one needs the financial background to qualify.
This has implications for how the board recruits independent directors in the first place. A small biopharma board that has filled its independent seats with scientific advisors, regulatory experts, and seasoned biotech executives — all valuable contributions — and that has not specifically prioritized financial expertise will find, as it approaches a public listing, that it does not have anyone who can chair an audit committee. The remediation at that stage is to recruit a new director specifically for the audit chair role, which is workable but constraining: the seat that director takes is a seat that cannot be used for any of the other expertise gaps the board may have wanted to fill.
The practical implication is that board composition planning should be done with the audit committee in mind from the beginning, not as a retroactive correction. At least one of the independent directors should be selected with the explicit understanding that they will eventually chair the audit committee, and they should be brought onto the board early enough to develop the company-specific knowledge that the audit chair role actually requires.
A second design choice that warrants early attention is the audit committee's relationship with the company's external auditor. The committee should be the body that selects the auditor, that negotiates the audit engagement letter, and that receives the auditor's reports — not the CFO. In small companies, this division of responsibility is often blurred, and the audit committee functionally rubber-stamps decisions made by management. The discipline of having the committee actually own the auditor relationship matters when the company is small. It matters far more when the company is approaching a transaction, and the integrity of the audit relationship becomes a diligence point.
The third design choice is the whistleblower channel. Listing standards require public companies to maintain procedures for the confidential receipt of complaints about accounting or auditing matters, and the audit committee is the body that owns those procedures. In private companies, this infrastructure is often absent. The cost of building a real whistleblower channel — a third-party hotline, a defined committee escalation process, documented handling procedures — is modest, and the protection it provides becomes significant in any situation where the company faces allegations of misconduct. Boards that wait to build this infrastructure until the company is preparing to go public are building it under time pressure and on top of years of organizational habits that may not support it.
The Compensation Committee
The Compensation Committee is the second committee that meaningfully needs to exist in a small biopharma, but its work in a clinical-stage company is different from the work that a large-cap compensation committee performs.
The standard large-cap compensation committee spends most of its time on executive compensation design: peer benchmarking, equity grant philosophy, performance metric calibration, say-on-pay engagement with shareholders, and the technical work of running an executive compensation program for a company with many executives and a complex equity plan. In a clinical-stage biopharma with eight to twelve employees and three executive officers, this work is much smaller in scope. The compensation committee's most consequential decisions are usually two: the CEO's compensation arrangement, and the company-wide equity plan.
The CEO compensation arrangement is the decision that matters most, because the CEO's compensation in a venture-backed clinical-stage company is being set by people — investor directors — who have a direct economic interest in how it is structured. The conflict is structural and unavoidable. The investor directors want the CEO motivated and retained, but they also want to preserve the equity pool for future hires and protect their ownership from dilution. An independent compensation committee provides the structural buffer that allows these competing interests to be balanced through a process that is at least nominally arms-length.
In a five-seat board with three independents, the compensation committee membership is typically two or three of those independents. The CEO is excluded as a matter of basic governance. Investor directors are often excluded as well, particularly for decisions about their own portfolio company's CEO. The result, in many small biopharma boards, is that the compensation committee is the same three independents who are also serving on the audit committee, working through different agendas. This is not ideal in textbook governance terms, but it is unavoidable in a five-seat board, and it works as long as the committee meetings are real meetings with their own preparation and their own substantive deliberation, not five-minute administrative formalities at the end of board meetings.
The company-wide equity plan is the other compensation committee decision that matters disproportionately. The size of the option pool, the vesting structure, the refresh cadence, and the treatment of acceleration provisions all have consequences that compound over the life of the company. Many small biopharma boards delegate this work too much to outside counsel, with the result that the equity plan is a generic document rather than an intentional governance tool. The compensation committee should own the equity plan as a substantive matter — understanding what it does, why each provision is structured as it is, and how the plan supports or undermines the company's hiring and retention strategy.
One practical note worth making explicit: small biopharma boards often hire compensation consultants only at the moment of a transaction or an IPO preparation, when the compensation committee suddenly needs benchmarking data to support its decisions. By that point, the company's existing compensation structure may be hard to defend, and the committee may find itself ratifying decisions that were made organically over years without the discipline of consultant input. Engaging a compensation consultant earlier — well before a transaction is in sight — gives the committee the analytic foundation to make better decisions in real time, and is significantly less expensive than the alternative.
The Nominating and Governance Committee
Here the analysis diverges from the standard playbook. In large-cap governance, the Nominating and Governance Committee is one of the three foundational committees. In a five-seat clinical-stage biopharma, it usually should not exist as a separate committee at all.
The reason is that the work this committee is supposed to do — director recruitment, board composition planning, governance policy development, board evaluation, succession planning — is work that, in a small company, requires the engagement of the full board. Director recruitment in a venture-backed biopharma is not a process that a committee runs on the board's behalf. It is a process that the lead investor, the CEO, and the independent directors all participate in directly, often through their own networks. Constituting a formal committee to manage this process adds bureaucratic structure without adding governance value, and it can produce the perverse outcome of excluding investor directors from a process they need to be part of.
The same applies to governance policy and board evaluation. The substantive work of evaluating the board's own effectiveness, of revisiting committee charters, of considering whether the board's composition still matches the company's stage — this work belongs to the full board, in executive session, with the lead independent director or board chair facilitating. Carving it off into a committee dilutes rather than concentrates the engagement.
The exception is when the company is preparing for a public listing. At that point, US listing standards require either an independent nominating committee or that nominations be approved by a majority of independent directors. Most companies opt for the committee structure as the cleaner approach, and at that point the nominating and governance committee becomes a real entity. But before that moment, in the years when the company is private, treating it as a separate committee is more form than substance.
What does need to happen in the meantime is that the work the committee would do still has to get done. The board still has to plan its composition. It still has to evaluate its own effectiveness honestly. It still has to develop and maintain its governance policies. The discipline is to do this work as a full board, on a defined cadence, rather than allowing it to happen only when a financing or a transaction forces the question.
The Case for a Science and Research Committee
A Science and Research Committee — sometimes called a Science and Technology Committee or an R&D Committee — is the committee that small biopharma boards most often fail to constitute and most often need.
The case for it is straightforward. Clinical development decisions are the most consequential decisions the company makes. They involve scientific judgment that is genuinely specialized, evidence that takes time to evaluate properly, and trade-offs that the full board often does not have the time or the expertise to work through in the depth they deserve. A committee of two or three directors with relevant scientific and clinical backgrounds, meeting on a defined cadence to engage with the Chief Medical Officer and the Chief Scientific Officer outside the time pressure of full board meetings, can produce a quality of oversight that the full board acting alone cannot match.
The case against it is also straightforward. In a five-seat board with three independents, asking those three independents to staff yet another committee is asking too much. The directors with the scientific backgrounds to make this committee meaningful are often the same ones who are also expected to chair audit or compensation, and there is a limit to how thin their engagement can be spread.
The resolution, in practice, is usually that small biopharma boards constitute a Science and Research Committee informally rather than formally. A subset of directors with relevant expertise meets with the CMO and CSO between board meetings, prepares the scientific portions of the board agenda, and works through complex clinical questions in advance. This is functionally a committee without being formally chartered as one. It works reasonably well when the directors involved are disciplined about it and when the CEO supports the arrangement. It works less well when the engagement is sporadic, when the committee's role is undefined, or when management views it as redundant.
The case for formalizing this arrangement — chartering an actual Science and Research Committee with defined membership, a defined cadence, and a defined relationship to the full board — becomes stronger as the company progresses through clinical development. By the time the company is running a Phase III trial or contemplating a regulatory submission, the volume and complexity of scientific oversight has typically grown to the point where ad hoc engagement is no longer sufficient. Boards that have not built the committee infrastructure by then often find themselves trying to build it under time pressure, often with new directors recruited specifically to staff it.
For most clinical-stage biopharma boards, the practical answer is to formalize the Science and Research Committee earlier than the company thinks it needs to. The cost of having a chartered committee that meets quarterly is low. The benefit, when the company hits the moment where a complex scientific decision needs deep board engagement, is significant.
Special Committees
A note on special committees, because they recur often enough in clinical-stage biopharma to deserve their own treatment.
Special committees are committees of independent directors constituted for a specific purpose, usually with a defined duration and a defined mandate. The most common contexts are evaluating a transaction in which the CEO or a significant shareholder has a conflict of interest, conducting an internal investigation into allegations of misconduct, and managing a sale process. Special committees are not part of the standing committee structure, but the board's capacity to constitute one quickly and run it effectively is a meaningful governance capability.
The design choices that make special committees work — independence of membership, authority to retain independent counsel and advisors, a clear mandate, and direct reporting to the full board — are the same choices that determine whether the committee provides the governance protection it is supposed to provide. A special committee that is constituted in form but that does not actually exercise its authority independently is worse than no committee at all, because it provides a veneer of process protection without the substance.
The board's preparation for special committees is largely a matter of cultural and structural readiness. A board that has built genuine independence into its standing committees, that has worked with outside counsel directly, and that has practiced executive sessions without management is a board that can constitute a special committee quickly when one is needed. A board that has done none of these things will find that it does not have the muscle memory to make a special committee work, even when one is properly constituted.
What This Looks Like in Practice
Putting this together, a clinical-stage biopharma board with five to seven seats typically operates with the following committee structure:
A formal Audit Committee, composed of independent directors, chaired by a director with financial expertise, meeting at least quarterly and engaging with the external auditor in executive session at every meeting. A formal Compensation Committee, composed of independent directors, meeting at least three times a year, with the discipline of treating its work as substantive rather than administrative. An informal Science and Research engagement, which should become a formal committee earlier than the board thinks it needs to. No separate Nominating and Governance Committee until the company is approaching a public listing or otherwise needs the formal structure. The capacity to constitute special committees quickly when circumstances require it.
The work of the committees that the board does not separately constitute — nominating, governance, risk — gets done by the full board, on a defined cadence, with the discipline of treating it as substantive work rather than something that happens by accident.
The committee structure should evolve as the company evolves. The board that is appropriately structured for a Series B company is not the board that is appropriately structured for a company preparing to file an S-1. Board composition planning, which was the subject of an earlier article in this pillar, and committee structure planning should be conducted together, on the same cadence, and with the same forward-looking discipline.
The point of committees is not to mirror the structures that large companies use. It is to allocate the board's scarce oversight capacity to the work that most needs depth, independence, and structural authority. In a five-seat biopharma, that allocation looks different from what the governance manuals describe. Done well, it produces better oversight than the full architecture would in the same company, because it focuses the work where the work actually matters.
Lawrence Fine is CEO of AGCP Farmacêuticos and has direct biopharma board experience through Phase II clinical trials and successful exits.